JP2008514203A5 - - Google Patents

Download PDF

Info

Publication number
JP2008514203A5
JP2008514203A5 JP2007533758A JP2007533758A JP2008514203A5 JP 2008514203 A5 JP2008514203 A5 JP 2008514203A5 JP 2007533758 A JP2007533758 A JP 2007533758A JP 2007533758 A JP2007533758 A JP 2007533758A JP 2008514203 A5 JP2008514203 A5 JP 2008514203A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
acid molecule
filovirus
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007533758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514203A (ja
JP5046941B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/034798 external-priority patent/WO2006037038A1/en
Publication of JP2008514203A publication Critical patent/JP2008514203A/ja
Publication of JP2008514203A5 publication Critical patent/JP2008514203A5/ja
Application granted granted Critical
Publication of JP5046941B2 publication Critical patent/JP5046941B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007533758A 2004-09-27 2005-09-27 エボラ及び他のウイルスに対する防御に最適化されたワクチン Expired - Lifetime JP5046941B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US61388304P 2004-09-27 2004-09-27
US60/613,883 2004-09-27
US67760605P 2005-05-03 2005-05-03
US60/677,606 2005-05-03
US67976705P 2005-05-10 2005-05-10
US60/679,767 2005-05-10
US70169405P 2005-07-22 2005-07-22
US60/701,694 2005-07-22
US71587405P 2005-09-09 2005-09-09
US60/715,874 2005-09-09
PCT/US2005/034798 WO2006037038A1 (en) 2004-09-27 2005-09-27 Optimized vaccines to provide protection against ebola and other viruses

Publications (3)

Publication Number Publication Date
JP2008514203A JP2008514203A (ja) 2008-05-08
JP2008514203A5 true JP2008514203A5 (https=) 2008-11-13
JP5046941B2 JP5046941B2 (ja) 2012-10-10

Family

ID=35695786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533758A Expired - Lifetime JP5046941B2 (ja) 2004-09-27 2005-09-27 エボラ及び他のウイルスに対する防御に最適化されたワクチン

Country Status (7)

Country Link
US (2) US8101739B2 (https=)
EP (1) EP1797113B1 (https=)
JP (1) JP5046941B2 (https=)
AU (1) AU2005289439B2 (https=)
CA (1) CA2581840C (https=)
IL (1) IL182225A (https=)
WO (1) WO2006037038A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
US7947286B2 (en) 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
CA2733104C (en) * 2008-08-07 2015-07-14 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Optimized promoter sequence
US9526777B2 (en) * 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
DK2655604T3 (en) 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
EP3896759A1 (en) 2011-10-05 2021-10-20 OneD Material, Inc. Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
CA3194125A1 (en) * 2012-04-12 2013-10-17 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2016513115A (ja) * 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
BR112016029579A2 (pt) 2014-06-26 2017-08-22 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PT3188753T (pt) 2014-09-03 2020-03-25 Bavarian Nordic As Métodos e composições para induzir imunidade protetora contra infeção por filovírus
CA2960096A1 (en) 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
EP3188752A2 (en) * 2014-09-03 2017-07-12 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
EP3233113A1 (en) * 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
GB201502209D0 (en) 2015-02-10 2015-03-25 Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro Filovirus therapy
WO2016138312A2 (en) * 2015-02-25 2016-09-01 Vanderbilt University Antibody-mediated neutralization of marburg virus
US11135280B2 (en) * 2016-03-28 2021-10-05 Integrated Biotherapeutics, Inc. Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
CA3107083A1 (en) * 2018-08-13 2020-02-20 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers
WO2022226060A1 (en) * 2021-04-21 2022-10-27 Vanderbilt University Antibody cocktail for treatment of ebolavirus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1999032147A1 (en) 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection
CA2776391C (en) 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050255123A1 (en) * 2002-04-30 2005-11-17 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor

Similar Documents

Publication Publication Date Title
JP2008514203A5 (https=)
JP2023512519A5 (https=)
US10273269B2 (en) High potency immunogenic zika virus compositions
US7528223B2 (en) Antigens encoded by alternative reading frames from pathogenic viruses
US8435535B2 (en) Fusion proteins of HIV regulatory/accessory proteins
JP2008529558A5 (https=)
JP2010500399A5 (https=)
JP2013501038A5 (https=)
JP2008530245A5 (https=)
JP2013500015A5 (https=)
JP2019519252A5 (https=)
JP2004518631A5 (https=)
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
JP2006506097A5 (https=)
US10729762B2 (en) HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
JP2004501646A5 (https=)
WO2008154867A1 (fr) Composé immunogénique
JP2009501012A5 (https=)
CN115698295A (zh) 一种疫苗试剂和接种方法
CN103298936A (zh) 具有新型流感病毒来源的血凝素蛋白基因的重组痘苗病毒
JP2024523329A5 (https=)
JP2011088864A (ja) インフルエンザウイルスに対するベクターワクチン
WO2022127820A1 (zh) 病原样抗原疫苗及其制备方法
JP2024543954A5 (https=)
JP2014505700A (ja) 抗原性ｇｌｙ１ポリペプチド